<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40673517</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2047-9980</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>15</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>Journal of the American Heart Association</Title><ISOAbbreviation>J Am Heart Assoc</ISOAbbreviation></Journal><ArticleTitle>Cost-Effectiveness of Drug-Coated Balloons in the Treatment of Coronary Small Vessel Disease: A Report From the BASKET-SMALL 2 Randomized Controlled Trial.</ArticleTitle><Pagination><StartPage>e037214</StartPage><MedlinePgn>e037214</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e037214</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1161/JAHA.124.037214</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Drug-coated balloons (DCB) are noninferior to second-generation drug-eluting stents (DES) in the treatment of small vessel coronary artery disease regarding major adverse cardiac events (MACE). However, the economic implication of this finding is unclear.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In the BASKET-SMALL 2 study (Basel Stent Kosten-Effektivit&#xe4;ts Trial: Drug-Coated Balloons Versus Drug-Eluting Stents in Small Vessel Interventions 2), 738 patients were treated with either DCB or DES and followed up regarding MACE, that is, target vessel revascularization, myocardial infarction, or cardiac death, over 3&#x2009;years. A cost-effectiveness analysis was performed using German diagnosis-related group data to evaluate total expected costs and quality-adjusted life expectancy, expressed in quality-adjusted life-years, for the entire cohort and each treatment option.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">DCB led to fewer MACE than DES (14.5% versus 15.3%) but also reduced quality-adjusted life expectancy during the 3-year follow-up (2.35 versus 2.36 quality-adjusted life-years). Regarding direct costs, DCB was less expensive than DES: 5243 versus 5341 EUR during the first 3&#x2009;years. The incremental cost-effectiveness ratio for DES versus DCB was 6863 EUR per quality-adjusted life-year gained, whereas DCB was more effective and less costly than DES in terms of MACE avoided. Sensitivity analyses emphasized the uncertainty in the results.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Despite reducing the probability of MACE, in terms of quality-adjusted life expectancy DCB was less cost effective than DES at 3&#x2009;years in the treatment of small vessel coronary artery disease, although results varied substantially when accounting for uncertainty in model parameters.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cattaneo</LastName><ForeName>Marco E G V</ForeName><Initials>MEGV</Initials><Identifier Source="ORCID">0000-0002-6610-8431</Identifier><AffiliationInfo><Affiliation>University Hospital Basel, Department of Clinical Research University of Basel Basel Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coslovsky</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7678-7354</Identifier><AffiliationInfo><Affiliation>University Hospital Basel, Department of Clinical Research University of Basel Basel Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malkin</LastName><ForeName>Samuel J P</ForeName><Initials>SJP</Initials><Identifier Source="ORCID">0000-0003-1306-7784</Identifier><AffiliationInfo><Affiliation>Ossian Health Economics and Communications GmbH Basel Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fahrni</LastName><ForeName>Gregor</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University Hospital Basel, Department of Clinical Research University of Basel Basel Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Triemli Hospital Z&#xfc;rich Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University Hospital Basel, Department of Cardiology University of Basel Basel Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilgen</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>University Hospital Basel, Department of Clinical Research University of Basel Basel Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheller</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-7139-5298</Identifier><AffiliationInfo><Affiliation>Clinical and Experimental Interventional Cardiology Saarland University Homburg Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeger</LastName><ForeName>Raban V</ForeName><Initials>RV</Initials><Identifier Source="ORCID">0000-0003-1290-5491</Identifier><AffiliationInfo><Affiliation>University Hospital Basel, Department of Clinical Research University of Basel Basel Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Triemli Hospital Z&#xfc;rich Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Heart Assoc</MedlineTA><NlmUniqueID>101580524</NlmUniqueID><ISSNLinking>2047-9980</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020099">Coated Materials, Biocompatible</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002317">Cardiovascular Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003324" MajorTopicYN="Y">Coronary Artery Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054855" MajorTopicYN="Y">Drug-Eluting Stents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019057" MajorTopicYN="N">Quality-Adjusted Life Years</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015906" MajorTopicYN="Y">Angioplasty, Balloon, Coronary</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020099" MajorTopicYN="Y">Coated Materials, Biocompatible</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062906" MajorTopicYN="Y">Cardiac Catheters</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002317" MajorTopicYN="Y">Cardiovascular Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cost&#x2010;effectiveness analysis</Keyword><Keyword MajorTopicYN="N">drug&#x2010;coated balloons</Keyword><Keyword MajorTopicYN="N">major adverse cardiac events</Keyword><Keyword MajorTopicYN="N">percutaneous coronary intervention</Keyword><Keyword MajorTopicYN="N">quality&#x2010;adjusted life expectancy</Keyword><Keyword MajorTopicYN="N">second&#x2010;generation drug&#x2010;eluting stents</Keyword><Keyword MajorTopicYN="N">small vessel disease</Keyword></KeywordList><CoiStatement>Gregor Fahrni, and Raban V. Jeger received grants to the institution from Abbott, Amgen, AstraZeneca, Bayer, Biosense Webster, B. Braun Melsungen AG, Biotronik, Boston Scientific, Bristol&#x2010;Myers Squibb, Cardionovum, Cordis, Daiichi Sankyo, Edwards Lifesciences, GE Medical Systems, MCM Medsys, Medtronic, Novartis, Pfizer, Terumo, and Vascular Medical GmbH. Bruno Scheller is a shareholder of InnoRa GmbH, Berlin, Germany and has received lecture fees from B. Braun and Medtronic. Samuel J. P. Malkin is an employee of Ossian Health Economics and Communications GmbH, which received consulting fees from University Hospital Basel to support preparation of the analysis. The remaining authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>8</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40673517</ArticleId><ArticleId IdType="pmc">PMC12449968</ArticleId><ArticleId IdType="doi">10.1161/JAHA.124.037214</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jeger RV, Farah A, Ohlow MA, Mangner N, M&#xf6;bius&#x2010;Winkler S, Leibundgut G, Weilenmann D, W&#xf6;hrle J, Richter S, Schreiber M, et&#xa0;al. Drug&#x2010;coated balloons for small coronary artery disease (BASKET&#x2010;SMALL 2): an open&#x2010;label randomised non&#x2010;inferiority trial. Lancet. 2018;392:849&#x2013;856. doi: 10.1016/S0140-6736(18)31719-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31719-7</ArticleId><ArticleId IdType="pubmed">30170854</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeger RV, Farah A, Ohlow MA, Mangner N, M&#xf6;bius&#x2010;Winkler S, Weilenmann D, W&#xf6;hrle J, Stachel G, Markovic S, Leibundgut G, et&#xa0;al. Long&#x2010;term efficacy and safety of drug&#x2010;coated balloons versus drug&#x2010;eluting stents for small coronary artery disease (BASKET&#x2010;SMALL 2): 3&#x2010;year follow&#x2010;up of a randomised, non&#x2010;inferiority trial. Lancet. 2020;396:1504&#x2013;1510. doi: 10.1016/S0140-6736(20)32173-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32173-5</ArticleId><ArticleId IdType="pubmed">33091360</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilgen N, Farah A, Scheller B, Ohlow MA, Mangner N, Weilenmann D, W&#xf6;hrle J, Jamshidi P, Leibundgut G, M&#xf6;bius&#x2010;Winkler S, et&#xa0;al. Drug&#x2010;coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET&#x2010;SMALL 2. Clin Cardiol. 2018;41:569&#x2013;575. doi: 10.1002/clc.22942</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.22942</ArticleId><ArticleId IdType="pmc">PMC6001703</ArticleId><ArticleId IdType="pubmed">29527709</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura K, Leber AW, Sohns C, Roser M, Boldt LH, Kleber FX, Haverkamp W, Dorenkamp M. Cost&#x2010;effectiveness of paclitaxel&#x2010;coated balloon angioplasty and paclitaxel&#x2010;eluting stent implantation for treatment of coronary in&#x2010;stent restenosis in patients with stable coronary artery disease. Clin Res Cardiol. 2012;101:573&#x2013;584. doi: 10.1007/s00392-012-0428-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-012-0428-2</ArticleId><ArticleId IdType="pubmed">22350752</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorenkamp M, Boldt J, Leber AW, Sohns C, Roser M, Boldt LH, Haverkamp W, Bonaventura K. Cost&#x2010;effectiveness of paclitaxel&#x2010;coated balloon angioplasty in patients with drug&#x2010;eluting stent restenosis. Clin Cardiol. 2013;36:407&#x2013;413. doi: 10.1002/clc.22130</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/clc.22130</ArticleId><ArticleId IdType="pmc">PMC6649637</ArticleId><ArticleId IdType="pubmed">23595957</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron SJ, Chinnakondepalli K, Magnuson EA, Kandzari DE, Puskas JD, Ben&#x2010;Yehuda O, van Es GA, Taggart DP, Morice MC, Lembo NJ, et&#xa0;al. Quality&#x2010;of&#x2010;life after Everolimus&#x2010;eluting stents or bypass surgery for left&#x2010;Main disease: results from the EXCEL trial. J Am Coll Cardiol. 2017;70:3113&#x2013;3122. doi: 10.1016/j.jacc.2017.10.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2017.10.036</ArticleId><ArticleId IdType="pubmed">29097293</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg P, Galper BZ, Cohen DJ, Yeh RW, Mauri L. Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug&#x2010;eluting stents. Am Heart J. 2015;169:222&#x2013;233.e5. doi: 10.1016/j.ahj.2014.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2014.11.002</ArticleId><ArticleId IdType="pmc">PMC4407277</ArticleId><ArticleId IdType="pubmed">25641531</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen DJ, Taira DA, Berezin R, Cox DA, Morice MC, Stone GW, Grines CL. Cost&#x2010;effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent&#x2010;PAMI) trial. Circulation. 2001;104:3039&#x2013;3045.</Citation><ArticleIdList><ArticleId IdType="pubmed">11748097</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew D, De Abreu Louren&#xe7;o R, Adena M, Chim L, Aylward P. Cost&#x2010;effectiveness of 12&#x2010;month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes. Clin Ther. 2013;35:1110&#x2013;1117.e9.</Citation><ArticleIdList><ArticleId IdType="pubmed">23891361</ArticleId></ArticleIdList></Reference><Reference><Citation>
Institute for Quality and Efficiency in Health Care (IQWiG)
. IQWiG General Methods &#x2010; Version 6.1 [Internet]. 2022. https://www.iqwig.de/methoden/general&#x2010;methods_version&#x2010;6&#x2010;1.pdf
</Citation><ArticleIdList><ArticleId IdType="pubmed">27403465</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeitouni M, Silvain J, Guedeney P, Kerneis M, Yan Y, Overtchouk P, Barthelemy O, Hauguel&#x2010;Moreau M, Choussat R, Helft G, et&#xa0;al. Periprocedural myocardial infarction and injury in elective coronary stenting. Eur Heart J. 2018;39:1100&#x2013;1109. doi: 10.1093/eurheartj/ehx799</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehx799</ArticleId><ArticleId IdType="pubmed">29365133</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Faunce T. Decision&#x2010;analytical modelling in health&#x2010;care economic evaluations. Eur J Health Econ. 2008;9:313&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">17943332</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser C, Brunner&#x2010;La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, Bernheim A, Zutter A, Zellweger M, Grize L, et&#xa0;al. Incremental cost&#x2010;effectiveness of drug&#x2010;eluting stents compared with a third&#x2010;generation bare&#x2010;metal stent in a real&#x2010;world setting: randomised Basel Stent Kosten Effektivit&#xe4;ts Trial (BASKET). Lancet. 2005;366:921&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pubmed">16154019</ArticleId></ArticleIdList></Reference><Reference><Citation>La Brunner&#x2010; Rocca HP, Kaiser C, Bernheim A, Zellweger MJ, Jeger R, Buser PT, Osswald S, Pfisterer M. Cost&#x2010;effectiveness of drug&#x2010;eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivit&#xe4;ts Trial (BASKET): an 18&#x2010;month analysis. Lancet. 2007;370:1552&#x2013;1559. doi: 10.1016/S0140-6736(07)61660-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61660-2</ArticleId><ArticleId IdType="pubmed">17980734</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeger RV, Kaiser C, Mangner N, Kleber FX, Scheller B. Causes of death after treatment of small coronary artery disease with paclitaxel&#x2010;coated balloons. Clin Res Cardiol. 2021;110:307&#x2013;311. doi: 10.1007/s00392-020-01674-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-020-01674-1</ArticleId><ArticleId IdType="pubmed">32500165</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, Alfonso F, Latib A, Ong PJ, Rissanen TT, et&#xa0;al. Drug&#x2010;coated balloons for coronary artery disease: third report of the international DCB consensus group. JACC Cardiovasc Interv. 2020;13:1391&#x2013;1402. doi: 10.1016/j.jcin.2020.02.043</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcin.2020.02.043</ArticleId><ArticleId IdType="pubmed">32473887</ArticleId></ArticleIdList></Reference><Reference><Citation>Merinopoulos I, Gunawardena T, Corballis N, Tsampasian V, Vassiliou V, Eccleshall S, Ryding A, Xydopoulos G. Cost effectiveness analysis of drug coated balloon only angioplasty for de novo coronary artery disease. Catheter Cardiovasc Interv. 2023;102:987&#x2013;996. doi: 10.1002/ccd.30878</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccd.30878</ArticleId><ArticleId IdType="pubmed">37925618</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhold T, Lindig C, Willich S, Br&#xfc;ggenj&#xfc;rgen B. The costs of myocardial infarction&#x2010;a longitudinal analysis using data from a large German health insurance company. J Public Health. 2011;19:579&#x2013;586. doi: 10.1007/s10389-011-0420-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10389-011-0420-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens E, Sinner MF, Siebermair J, Raufhake C, Beckmann BM, Veith S, D&#xfc;vel D, Steinbeck G, K&#xe4;&#xe4;b S. Incidence of sudden cardiac death in Germany: results from an emergency medical service registry in Lower Saxony. Europace. 2014;16:1752&#x2013;1758. doi: 10.1093/europace/euu153</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euu153</ArticleId><ArticleId IdType="pmc">PMC4241885</ArticleId><ArticleId IdType="pubmed">25061228</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammer M, Lammert M, Mej&#xed;as SM, Kern W, Frier BM. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12:281&#x2013;290. doi: 10.3111/13696990903336597</Citation><ArticleIdList><ArticleId IdType="doi">10.3111/13696990903336597</ArticleId><ArticleId IdType="pubmed">20001570</ArticleId></ArticleIdList></Reference><Reference><Citation>
Management Consult Kestermann GmbH
. Gutachten zur ambulanten Notfallversorgung im Krankenhaus &#x2010; Fallkostenkalkulation und Strukturanalyse [Internet]. 2015. https://www.dkgev.de/media/file/19401.2015&#x2010;02&#x2010;17_Gutachten_zur_ambulanten_Notfallversorgung_im_Krankenhaus_2015.pdf
</Citation></Reference><Reference><Citation>Bock JO, Brettschneider C, Seidl H, Bowles D, Holle R, Greiner W, K&#xf6;nig HH. Ermittlung standardisierter Bewertungss&#xe4;tze aus gesellschaftlicher Perspektive f&#xfc;r die gesundheits&#xf6;konomische Evaluation. Gesundheitswesen. 2015;77:53&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">25025287</ArticleId></ArticleIdList></Reference><Reference><Citation>
GKV&#x2010;Spitzenverband
, Verband der Privaten Krankenversicherung
, Deutschen Krankenhausgesellschaft
. Vereinbarung gem&#xe4;&#xdf; &#xa7; 10 Abs. 9 KHEntgG f&#xfc;r den Vereinbarungszeitraum 2020 [Internet]. 2019. https://www.gkv&#x2010;spitzenverband.de/media/dokumente/krankenversicherung_1/krankenhaeuser/budgetverhandlungen/bundesbasisfallwert/KH_BBFW_2020.pdf
</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>